A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)

OBJECTIVE: To evaluate the efficacy and safety of AVP-825, a drug–device combination of low-dose sumatriptan powder (22 mg loaded dose) delivered intranasally through a targeted Breath Powered device vs an identical device containing lactose powder (placebo device) in the treatment of migraine heada...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Headache
Autors principals: Cady, Roger K, McAllister, Peter J, Spierings, Egilius LH, Messina, John, Carothers, Jennifer, Djupesland, Per G, Mahmoud, Ramy A
Format: Artigo
Idioma:Inglês
Publicat: BlackWell Publishing Ltd 2015
Matèries:
Research Submissions
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4320758/
https://ncbi.nlm.nih.gov/pubmed/25355310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.12472
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars